ASTRAZEN

AstraZeneca Pharma India Share Price

 

 

Invest in AstraZeneca Pharma India with 3.24X leverage

Invest with MTF

Performance

  • Low
  • ₹8,647
  • High
  • ₹8,777
  • 52 Week Low
  • ₹6,620
  • 52 Week High
  • ₹10,691
  • Open Price₹8,698
  • Previous Close₹8,630
  • Volume6,215
  • 50 DMA₹8,692.02
  • 100 DMA₹8,803.33
  • 200 DMA₹8,636.45

Investment Returns

  • Over 1 Month + 1.26%
  • Over 3 Month -8.84%
  • Over 6 Month -2.06%
  • Over 1 Year + 17.54%

Smart Investing Starts Here Start SIP with AstraZeneca Pharma India for Steady Growth!

Invest Now

AstraZeneca Pharma India Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 109.3
  • PEG Ratio
  • 0.8
  • Market Cap Cr
  • 21,775
  • P/B Ratio
  • 27.3
  • Average True Range
  • 200.12
  • EPS
  • 92.47
  • Dividend Yield
  • 0.4
  • MACD Signal
  • -116.84
  • RSI
  • 58.34
  • MFI
  • 40.27

AstraZeneca Pharma India Financials

AstraZeneca Pharma India Technicals

EMA & SMA

Current Price
₹8,710.00
+ 80.5 (0.93%)
pointer
  • Bearish Moving Average 5
  • Bullish Moving Average 11
  • 20 Day
  • ₹8,513.75
  • 50 Day
  • ₹8,692.02
  • 100 Day
  • ₹8,803.33
  • 200 Day
  • ₹8,636.45

Resistance and Support

8711.17 Pivot Speed
  • R3 8,906.33
  • R2 8,841.67
  • R1 8,775.83
  • S1 8,645.33
  • S2 8,580.67
  • S3 8,514.83

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

AstraZeneca Pharma India Ltd. is a global, science-led pharmaceutical company dedicated to transforming healthcare through innovative medicines in oncology, biopharmaceuticals, and rare diseases. it focuses on improving patient outcomes and advancing healthcare worldwide.

Astrazeneca Pharma India has an operating revenue of Rs. 2,006.17 Cr. on a trailing 12-month basis. An annual revenue growth of 32% is outstanding, Pre-tax margin of 9% is okay, ROE of 15% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. It is currently FORMING a base in its weekly chart and is trading around 19% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 87 which is a GOOD score indicating consistency in earnings, a RS Rating of 68 which is FAIR indicating the recent price performance, Buyer Demand at D- which indicates heavy supply, Group Rank of 74 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

AstraZeneca Pharma India Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-11 Quarterly Results
2025-11-07 Quarterly Results
2025-08-14 Quarterly Results
2025-05-30 Audited Results & Dividend
2025-02-11 Quarterly Results
Date Purpose Remarks
2025-07-18 FINAL Rs.32.00 per share(1600%)Dividend
2024-07-05 FINAL Rs.24.00 per share(1200%)Dividend
2023-07-14 FINAL Rs.16.00 per share(800%)Dividend
2022-07-08 FINAL Rs.8.00 per share(400%)Final Dividend
2021-08-20 INTERIM Rs.2.00 per share(100%)Interim Dividend
View AstraZeneca Pharma India Dividend History Arrow

AstraZeneca Pharma India F&O

AstraZeneca Pharma India Shareholding Pattern

75%
5.43%
0.05%
2.71%
0%
14.14%
2.67%

About AstraZeneca Pharma India

  • NSE Symbol
  • ASTRAZEN
  • BSE Symbol
  • 506820
  • Managing Director
  • Mr. Praveen Rao Akkinepally
  • ISIN
  • INE203A01020

Similar Stocks to AstraZeneca Pharma India

AstraZeneca Pharma India FAQs

AstraZeneca Pharma India share price is ₹8,710 As on 03 February, 2026 | 20:18

The Market Cap of AstraZeneca Pharma India is ₹21775 Cr As on 03 February, 2026 | 20:18

The P/E ratio of AstraZeneca Pharma India is 109.3 As on 03 February, 2026 | 20:18

The PB ratio of AstraZeneca Pharma India is 27.3 As on 03 February, 2026 | 20:18

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23